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Abstract
Zika virus (ZIKV) is a mosquito-borne positive sense RNA virus. Recently, ZIKV emerged
into the Western hemisphere as a human health threat, with severe disease associated with
developmental and neurological complications. The structural envelope protein of ZIKV and
other neurotropic flaviviruses contains an extended CD-loop relative to non-neurotropic fla-
viviruses, and has been shown to augment ZIKV stability and pathogenesis. Here we show
that shortening the CD-loop in ZIKV attenuates the virus in mice, by reducing the ability to
invade and replicate in the central nervous system. The CD-loop mutation was genetically
stable following infection in mice, though secondary site mutations arise adjacent to the
CD-loop. Importantly, while shortening of the CD-loop attenuates the virus, the CD-loop
mutant maintains antigenicity in immunocompetent mice, eliciting an antibody response that
similarly neutralizes both the mutant and wildtype ZIKV. These findings suggest that the
extended CD-loop in ZIKV is a determinant of neurotropism and may be a target in live-
attenuated vaccine design, for not only ZIKV, but for other neurotropic flaviviruses.
Author summary
Zika virus (ZIKV) is a mosquito-transmitted virus that was recently introduced in Brazil
and subsequently spread throughout the Americas. ZIKV is highly similar to the related
dengue virus but causes unique disease outcomes including neurological disease in adults
and fetal developmental complications. The ZIKV envelope protein coats the surface of
the virus and allows entry into host cells. Here we investigate a portion of the ZIKV enve-
lope protein, the CD-loop, which extends further than in dengue virus, and its role in
ZIKV neurological disease. Our study finds that shortening the CD-loop reduces the
ability of ZIKV to replicate in neuronal cells, that the longer CD-loop is a key factor for
invasion of the central nervous system in mice, and that a deletion in the CD-loop is
genetically stable with passage. Additionally, we show that infection with the CD-loop
mutant induces a potent antibody response that can neutralize wildtype ZIKV, suggesting
it may offer protection in mice. Shortening of the ZIKV CD-loop, and the CD-loop of
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other neurotropic flaviviruses, could contribute to development of rapid, effective, and
safe vaccines.
Introduction
Zika virus (ZIKV) is a positive-sense single-stranded RNA flavivirus. Though first isolated in
1947 and after years of relatively benign infections throughout Southeast Asia, ZIKV was iden-
tified in large human disease outbreaks in Yap Island, French Polynesia, and then the Ameri-
cas [1–5]. ZIKV infection is asymptomatic in a majority of adult cases, but when symptomatic,
generally causes mild febrile illness [6, 7]. ZIKV infection has also been associated with more
severe disease, such as neurological complications including Guillain-Barré syndrome [7–10].
Additionally, ZIKV infection during pregnancy is linked to microcephaly and fetal demise
[11, 12].
The ability of ZIKV to cause neurological disease is not unique among flaviviruses [13].
West Nile virus (WNV), Japanese encephalitis virus (JEV), and tick-borne encephalitis virus
(TBEV) also infect the central nervous system (CNS) and cause encephalitic disease. However,
dengue virus (DENV), a highly similar virus both genetically and antigenically, only very rarely
causes neurological or encephalitic disease [14, 15], highlighting a disconnect between disease
and virus relatedness. While the complete viral determinants of flavivirus neurotropism are
not fully known, there are several described conserved and divergent mechanisms [13]. For
example, multiple groups have shown that envelope protein glycosylation is necessary for
neurovirulence of WNV and ZIKV [16–19]. However, this glycosylation motif is conserved
between both neurotropic and non-neurotropic flaviviruses, indicating that it is not solely suf-
ficient for neurotropism. Additionally, several groups have identified novel neuronal ZIKV
receptors, such as AXL, that are not utilized by other neurotropic flaviviruses [20, 21].
Multiple groups have shown that ZIKV is more structurally stable than DENV, hypothesiz-
ing that it can persist longer in body compartments and fluids, potentially leading to an
increased chance of neuroinvasion [22–25]. One key difference between the structural enve-
lope proteins of neurotropic and hemorrhagic flaviviruses is the extension of the CD-loop by a
single amino acid [23, 24]. Though predicted to stabilize the virus via a network of hydrogen
bonds, we have previously shown that the extended loop itself, independent of hydrogen bond-
ing, is responsible for ZIKV’s structural and thermal stability [23, 24]. Additionally, shortening
of the CD-loop by a single amino acid (Δ346 ZIKV) attenuated the virus in a mouse model of
ZIKV pathogenesis [24]. Interestingly, while both viruses replicate in the periphery, the CD-
loop mutant was less likely to be found in the CNS of infected mice compared to wildtype
(WT) ZIKV. This suggests that the extended CD-loop, or the structural stability that it confers,
is important for neuropathogenesis.
In this study we further investigate the role of the ZIKV CD-loop in neurotropism and anti-
genicity. We find that the CD-loop mutant is delayed in disseminating to the brain, but once
present can replicate and cause lethal disease. Importantly, when delivered via intracranial
infection, Δ346 ZIKV is still less pathogenic, indicating that the attenuated phenotype is not
solely due to a defect in neuroinvasion. While the Δ346 deletion is genetically stable after long-
term in vivo infection, secondary site mutations emerge in the envelope glycoprotein. A suc-
cessful ZIKV vaccine should have no risk of neurological complications in immunocompetent
populations, and as our shortened CD-loop virus results in decreased neuropathogenicity, we
characterized the antibody response elicited by the Δ346 virus in mice. Mice infected with the
Δ346 mutant mount an antibody response that similarly neutralizes both Δ346 and WT ZIKV
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PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007212 March 7, 2019 2 / 14
Competing interests: The authors have declared
that no competing interests exist.
in cell culture. Together, this data suggests that shortening the CD-loop of ZIKV results in
decreased neurovirulence while maintaining wildtype ZIKV antigenicity.
Results
ZIKV CD-loop mutant is attenuated in a neuronal cell line
We have previously shown that shortening of the ZIKV CD-loop results in attenuated replica-
tion in both mammalian Vero and mosquito C6/36 cells [24]. To determine if the Δ346 virus is
attenuated in neuronal cells, we performed a single step growth curve in the human neuroblas-
toma cell line SH-SY5Y, which have been previously used as an in vitro neurological model
of ZIKV replication (Fig 1) [26–28]. Though Δ346 ZIKV replicated similarly to WT ZIKV at
early time points, the Δ346 virus was slightly attenuated throughout most of the time course
before finally reaching equivalent peak titers (p<0.05). This indicates that despite minor atten-
uation relative to WT ZIKV, the CD-loop mutant is capable of infection and replication in
neuronal cells.
Δ346 virus can reach and replicate in the brain in immunocompromised
mice
We previously explored the Δ346 mutant in 11-week-old IFNAR-/- IFNGR-/- mice on a
C57BL/6J background (herein referred to as IFNAGR-/-), observing severe attenuation with
no development of disease [24]. Younger mice are more susceptible to ZIKV disease [29],
allowing us to study the Δ346 mutant in a more permissive model. To determine if the Δ346
ZIKV pathogenesis attenuation also occurs in younger mice, we infected 8- to 10-week-old
IFNAGR-/- mice and monitored weight loss, lethality and viral loads in various tissues (Figs 2–
3). Mice infected with WT ZIKV all succumb to disease by day 15 post infection, whereas
Fig 1. Δ346 mutant is attenuated in neuronal cell line. Growth curve of SH-SY5Y cells infected at an MOI of 1 in
triplicate wells. Infectious virus titer (FFU/ml) was determined on C6/36 cells. Two-factor ANOVA followed by Sidak’s
multiple comparison was conducted on log-transformed data. � represents p< 0.05. Dotted line represents limit of
detection. Data points not detected are plotted at half the limit of detection. Error bars represent standard deviation.
https://doi.org/10.1371/journal.pntd.0007212.g001
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lethality is delayed in Δ346 ZIKV infected mice (p<0.05) (Fig 2A and 2B). Increasing the infec-
tion dose of Δ346 ZIKV from 103 to 104 FFU did not increase lethality or weight loss, indicat-
ing that the attenuation phenotype is not directly dose-dependent (p>0.05) (Fig 2C and 2D).
On day six post infection, the Δ346 mutant replicated to lower titers in the serum, liver, spleen,
and kidneys compared to WT virus (p<0.05) (Fig 3A). Additionally, at this early time point,
there were fewer Δ346-infected mice with detectable virus in their brain and spinal cord com-
pared to WT ZIKV infected mice (p< 0.05) (Fig 3B).
IFNAGR-/- mice typically succumb to ZIKV infection due to neurological complications
caused by viral replication in the brain [29]. Moribund infected mice were harvested for organ
end point virus titers. Despite succumbing to disease at different rates (Fig 2A), nearly all WT
and Δ346 ZIKV infected mice cleared serum viremia by time of death (Fig 3C). Interestingly,
mice infected with either virus had comparable titers in the brain and spinal cord (p>0.05)
(Fig 3C), demonstrating that although the Δ346 virus is attenuated, it can eventually replicate
Fig 2. Δ346 virus is attenuated in IFNAGR-/- mice. (A-B) IFNAGR-/- mice were infected with 103 FFU of WT or Δ346 ZIKV via footpad infection and
monitored for (A) survival and (B) weight loss (n = 13 for each group). (C-D) Mice were infected with 103 or 104 FFU Δ346 ZIKV via footpad infection
and monitored for (C) survival and (D) weight loss (n = 13 and 4, respectively). Log-rank test was conducted on survival curves. � represents p< 0.05.
‘ns’ represents not statistically significant. Dotted line represents 100% starting weight. Error bars represent standard error of the mean.
https://doi.org/10.1371/journal.pntd.0007212.g002
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to high titers and cause encephalitic disease. Overall, shortening of the CD-loop results in
decreased dissemination of ZIKV to the brain and delayed mortality, but it still causes neuro-
logical disease in immunocompromised mice.
The Δ346 deletion is genetically stable in the brains of
immunocompromised mice
To determine if the Δ346 virus is genetically stable in IFNAGR-/- mice, we sequenced the enve-
lope gene of virus from the brains of mice infected via footpad with WT and Δ346 ZIKV. All
mice infected with the Δ346 mutant with detectible virus in their brain (Fig 3B and 3C) main-
tained the deletion of residue 346, demonstrating that this deletion is stable in vivo (Fig 4A).
However, viruses in these mice had envelope protein secondary site mutations (Fig 4A) that
were not detected in the virus stock (sequence available in S1 Data). At day six post infection,
100% of Δ346 ZIKV virus-positive mice contained a V391A substitution. By the end point,
virus from 60% of Δ346 ZIKV infected mice contained this same substitution, indicating this
residue might be important in dissemination to or replication in the CNS. Viruses from indi-
vidual mice also contained three other substitutions, however each of these mutations were
only present in virus from a single mouse, suggesting they are not common mutations. These
secondary site mutations, with the exception of G150E, are all structurally located near the
CD-loop, suggesting that they may have emerged as a consequence of the shortened CD-loop
Fig 3. Δ346 mutant is attenuated early but reaches similar end point titers in immunocompromised mice.
IFNAGR-/- mice were infected with 103 FFU of WT or Δ346 ZIKV via footpad infection. On day six post infection, (A)
serum, liver, spleen, kidney, (B) spinal cord, and brain were harvested and titered for infectious virus levels (n = 7 WT
and n = 6 Δ346 ZIKV infected mice). Moribund mice were harvested for (C) serum, spinal cord, and brain end-point
titer analysis (n = 4 for each group). Mann-Whitney tests were performed on log-transformed data. � represents
p< 0.05. Dotted line represents limit of detection. Data points not detected are plotted at half the limit of detection.
Error bars represent standard deviation.
https://doi.org/10.1371/journal.pntd.0007212.g003
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(Fig 4B and 4C). Importantly, none of these mutations emerged in mice infected with WT
ZIKV (Fig 4A), revealing that these substitutions arise specifically in the context of Δ346
ZIKV. It is possible that these secondary site mutations are functionally compensating for
decreased stability of the Δ346 or decreased fitness in the CNS. Future studies are necessary to
elucidate the precise impact of these mutations.
Shortened CD-loop mutant is attenuated in brain when delivered
intracranially
To determine if Δ346 ZIKV is able to replicate similarly to WT ZIKV in the brain, without the
barrier of dissemination into the CNS, we performed intracranial (IC) infections in IFNAGR-/-
and wildtype C57BL/6J mice. Following IC injection, immunocompromised mice infected
with the Δ346 mutant had delayed lethality relative to WT virus (p<0.05) (Fig 5A and 5B),
but succumb to infection more rapidly than when inoculated via footpad infection (Fig 2A
and 2B). CD-loop mutant infected mice have similar brain viral titers on days two and six
compared, and end point to WT ZIKV infected mice (Fig 5C). Wildtype C57BL/6J mice did
not show any signs of disease or viral replication in the CNS following IC infection with either
virus (Fig 5D–5F). Even when delivered to the brain, an immunopriveledged site, of immuno-
competent mice, neither virus is capable of causing disease. Overall, the shortened CD-loop
Fig 4. The Δ346 mutation is genetically stable in mice. The envelope gene of virus isolated from the brains of mice infected with Δ346 ZIKV via
footpad was sequenced. (A) Summary table showing the status of residue 346 and secondary site mutations present at timepoints indicated. ‘�’ denotes
out of mice with detectable virus in the brain. Secondary site mutations were not present in input stock virus or found in mice infected with WT ZIKV
(sequences available in supplementary data file). (B-C) The location of residue 346 (green) and secondary site mutations (cyan) shown on the ZIKV
envelope protein (PDB 5IZ7). (B) Top-down view of five-fold vertex or (C) side view of CD-loop on single envelope monomer.
https://doi.org/10.1371/journal.pntd.0007212.g004
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mutant is attenuated relative to WT ZIKV at replicating the CNS, causing delayed disease in
immunocompromised mice.
Δ346 mutant induces similar antibody response as WT virus in mice
As the Δ346 mutant is attenuated in neuropathogenesis, mutations that shorten the ZIKV
CD-loop may be incorporated into future live-attenuated vaccines. We have previously
shown that while the Δ346 virus is structurally destabilized, viruses produced in cell culture
are morphologically similar to WT ZIKV [24]. To determine if Δ346 ZIKV infection elicits an
antibody response similar to that of WT ZIKV infection, we infected C57BL/6J mice pretreated
with an IFNAR-blocking antibody and analyzed the anti-ZIKV antibodies. Mice infected with
WT or Δ346 ZIKV did not show any signs of disease, but supported acute viral replication
Fig 5. Δ346 virus is attenuated following intracranial infection. (A-C) IFNAGR-/- or (D-F) C57BL/6J mice were infected with 103 FFU of WT or
Δ346 ZIKV via intracranial infection and monitored for (A, D) survival and (B, E) weight loss (For IFNAGR-/- mice, n = 11 and 14 respectively. For
C57BL/6J mice, n = 15 and 14, respectively). (C, F) On days two and six post infection, brain tissue was harvested and titered for infectious virus levels
(For IFNAGR-/- mice, day 2: n = 4 WT and n = 5 Δ346 ZIKV infected mice; day 6: n = 2 WT and n = 3 Δ346 ZIKV infected mice. For C57BL/6J mice,
day 2: n = 4 WT and n = 5 Δ346 ZIKV infected mice; day 6: n = 4 for each group.). (C) Moribund IFNAGR-/- mice and (F) on day 21 post infection,
C57BL/6J mice, were harvested for end-point brain titer analysis (For IFNAGR-/- mice, n = 5 for each group. For C57BL/6J mice, n = 6 for each group.).
Log-rank test was conducted on survival curves. Two-factor ANOVA followed by Sidak’s multiple comparison was conducted on log-transformed titer
data. � represents p< 0.05. Dotted line represents 100% starting weight or limit of detection. Data points not detected are plotted at half the limit of
detection. Error bars represent (B, E) standard error of the mean or (C, F) standard deviation.
https://doi.org/10.1371/journal.pntd.0007212.g005
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with similar serum viremia on day three post infection (p>0.05) (Fig 6A and 6B). We next
evaluated the ability of WT and Δ346 ZIKV immune sera to bind and neutralize both WT
and Δ346 ZIKV viruses. WT ZIKV immune sera had similar levels of ZIKV-reactive IgG com-
pared to Δ346 sera, and both sera bound both viruses similarly (p>0.05) (Fig 6C). Despite
lower levels of total ZIKV antibodies, sera from Δ346-infected mice efficiently neutralized
both viruses, with neutralization titers similar to those of WT ZIKV sera (p>0.05) (Fig 6D).
Importantly, these data show that the Δ346 mutant maintains antigenicity and elicits neutraliz-
ing antibodies against WT ZIKV suggesting potential application as a part of a live-attenuated
vaccine approach.
Fig 6. Δ346 mutant induces antibody response similar to WT ZIKV infection. C57BL/6J mice were pretreated with anti-IFNAR1 blocking antibody,
infected with 103 FFU WT or Δ346 ZIKV via footpad infection, and (A) monitored for daily weight loss (n = 8 for each group). (B) On day three post
infection, blood was collected and titered to measure serum viremia (n = 5 mock infected mice, n = 8 for both infected groups). (C-D) Day 28 immune
sera was collected and analyzed for (C) IgG antibody binding to WT and Δ346 ZIKV via ELISA and (D) neutralization titer analysis via C6/36-based
focus reduction neutralization test (FRNT). Y-axis represents serum dilution factor required to neutralize 50% of infectious virus. One-factor ANOVA
followed by Tukey’s multiple comparisons test was conducted on log-transformed titer data. Two-factor ANOVA followed by Tukey’s multiple
comparisons test was conducted on binding and neutralization data. � represents p< 0.05. Dotted line represents 100% starting weight or limit of
detection. Data points not detected are plotted at half the limit of detection. Error bars represent (A) standard error of the mean or (B-D) standard
deviation.
https://doi.org/10.1371/journal.pntd.0007212.g006
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Discussion
Having previously characterized the extended ZIKV CD-loop as an important determinant of
stability and virulence [24], here we further examined the shortened CD-loop mutant virus.
The Δ346 mutant displays a mild growth defect in a neuronal cell line suggesting capacity to
replicate in the brain. In addition, we confirmed in vivo attenuation via the peripheral route of
infection in terms of dissemination to the CNS as well as replication in the brain relative to
WT ZIKV. The Δ346 mutation is genetically stable after in vivo infection. However, Δ346 virus
sequenced from the brains of mice reveal secondary site mutations near the CD-loop whose
functions are unknown, but may compensate for viral stability or neuropathogenicity. The sec-
ondary site mutations identified in this study may inform future structure-function studies of
the CD-loop in regards to ZIKV virion stability and pathogenesis, identifying key CD-loop
contacts critical in the ZIKV virion.
After intracranial infection, the Δ346 mutant was highly attenuated, demonstrating that in
addition to defects in neuroinvasion, the CD-loop mutant causes delayed encephalitic disease
when delivered directly to the CNS. While the CD-loop mutant displays attenuation, it is capa-
ble of eliciting antibodies that neutralize WT ZIKV, suggesting it still maintains proper ZIKV
antigenicity. While we do not know the mechanism of the Δ346 mutant attenuation beyond
virion stability, the shortened CD-loop may alter cellular tropism, particularly in the brain,
resulting in fewer infected cells and delayed disease. Defining the cell types infected by the
Δ346 mutant and WT ZIKV in tissues, specifically the brain, may provide insights into the
decreased disease phenotype.
The viral determinants that allow ZIKV and other neurotropic flaviviruses to invade and
replicate in the CNS are not fully understood [6, 7, 13]. Here, we show that shortening of the
CD-loop in the ZIKV envelope results in delayed neuroinvasion in immunocompromised
mice. This delayed neuroinvasion may be due stochastic differences in intra-host evolution of
the Δ346 virus developing secondary site mutations that increase fitness in the CNS.
Neurotropic flaviviruses WNV, JEV, and TBEV also share an extended CD-loop within the
envelope protein relative to hemorrhagic flaviviruses such as DENV [23]. Shortening the CD-
loop in other flaviviruses would be important in understanding if the CD-loop modulates sta-
bility and neurovirulence in other viruses. Within ZIKV strains, there is variation in the patho-
genicity of ZIKV isolates. Multiple groups have shown that Asian ZIKV strains, such as the
H/PF/2013 strain used in this study, are less neurovirulent than African strains [30, 31]. The
extended CD-loop is conserved among all ZIKV strains, thus we expect that shortening the
CD-loop in African ZIKV strains will also attenuate the virus, though the effects may be more
modest due to other determinants driving their increased neuropathogenicity.
Targeting the CD-loop may be a broadly applicable approach for flavivirus attenuation.
Groups have shown that glycosylation of the WNV envelope protein has been well studied
for its role in neurotropism, however, it is possible the extended CD-loop is an additional
viral determinant of neurotropism [16, 17]. Although speculative, a WNV CD-loop mutant
could be an important tool for studying CD-loop-mediated neurotropism, as WNV causes
encephalitic disease in immunocompetent mice [16, 17]. Relative to DENV, both ZIKV and
WNV have an extended CD-loop; however, the identity of residue 346 varies, with alanine
in ZIKV and valine in WNV. It remains unclear whether the length of the CD-loop or the
identity of the residue at position 346 is critical for pathogenesis. While several flavivirus
vaccines exist, the YFV vaccine is occasionally associated with rare complications [32–35].
Though YFV is non-neurotropic, it contains an extended CD-loop [23] and incorporation
of the Δ346 mutation into the YFV vaccine may further increase safety, while preserving
antigenicity and efficacy. Live-attenuated vaccines resulting from deletions, such as a
Zika virus CD-loop and neuropathogenesis
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shortened CD-loop, are also more likely to be genetically stable than attenuating substitution
mutations.
There are limitations of studying ZIKV pathogenesis in current animal models, including
the necessity of using immunocompromised mice due to the strong restriction of ZIKV by
murine interferon signaling [29, 36]. Circumventing the interferon restriction, via genetic
knockout mice or antibody blockade of the interferon response, permits ZIKV replication, but
limits our ability to study the intact immune response to infection. Additionally, the use of
immunocompromised mice with delayed viral clearance is anticipated to increase the likeli-
hood of accumulating secondary site mutations which may contribute to restored replication
fitness and pathogenesis. Mouse adapted ZIKV viruses and use of humanized or human
STAT2 knock-in mice may serve as better future models to understand innate and adaptive
responses [37]. As these models become more available, it will be important to study the kinet-
ics, pathogenesis, and genetic stability of Δ346 ZIKV in these more relevant, immunocompe-
tent models. These models will also be important in testing the genetic stability of Δ346 ZIKV
in an immunocompetent model.
Overall, this work highlights the importance of the extended CD-loop for ZIKV neuro-
pathobiology. The extended CD-loop is an important determinant for ZIKV dissemination
and CNS invasion, but also crucial for efficient replication in the brain. However, shortening
of the CD-loop does not abolish neuropathogenicity, highlighting the multifaceted nature of
ZIKV neurovirulence. Additionally, shortening of the ZIKV CD-loop, while attenuating the
virus, maintains antigenicity and may be utilized in next-generation vaccine design in combi-
nation with additional attenuating mutations in the genome that reduce chance of disease.
Methods
Viruses and cells
Viruses were generated using a ZIKV H/PF/2013 infectious clone as described previously [24,
38]. Low passage virus stocks were produced in C6/36 cells. C6/36 cells (ATCC CRL-1660)
were maintained in Minimum Essential Medium, supplemented with 5% fetal bovine serum
(FBS), 1% nonessential amino acids (NEAA), and 1% antibiotic-antimycotic (AA) and grown
in 5% CO2 at 32˚C. SH-SY-5Y cells (ATCC CRL-2266) were maintained in MEM:F12 supple-
mented with 10% FBS and 1% AA and grown in 5% CO2 at 37˚C.
Virus titering and immunostaining
Samples were titered on C6/36 cells as the particle to FFU ratio is more similar between WT
and Δ346 ZIKV than when titered on Vero cells [24]. Viruses were serially diluted and added
to C6/36 monolayers for one hour. Cells were then overlaid with OptiMEM supplemented
with 1% methylcellulose, 2% FBS, 1% NEAA, and 1% AA and incubated at 32˚C for 4–5 days.
Cells were gently washed with PBS and fixed in cold 50% acetone + 50% methanol, then
immunostained with either mouse anti-E MAb 4G2 or human anti-E MAb 1M7, HRP-labeled
secondary antibody, and developed with KPL TrueBlue substrate.
SH-SY5Y growth curve
Plates were seeded with SH-SY5Y cells one day prior to infection. Cells were infected in tripli-
cate at an MOI of 1 for two hours, then washed with PBS to remove unbound virus, and
replaced with fresh media. Every 24 hours, supernatant was sampled, and immediately frozen
at -80˚C. Samples were titered on C6/36 cells as described above. Two-factor ANOVA
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followed by Sidak’s multiple comparison was conducted on log-transformed data. Experiment
was performed once.
Ethics statement
This study was carried out in accordance with the recommendations for care and use of ani-
mals by the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health.
All animal work was performed in strict adherence to the Institutional Animal Care and Use
Committee (IACUC) and University of North Carolina at Chapel Hill policy. The protocol
[#16–090] was approved by the UNC’s IACUC (Permit Number A-3410-01).
Mouse infections
Footpad infections were performed in 8- to 10-week-old male and female IFNAGR-/- mice on
C57BL/6 background with 103 or 104 FFU of WT or Δ346 ZIKV in 10ul diluted in PBS into
the left hind footpad (n = 13 for each group). Infected mice were monitored daily for weight
loss and clinical signs of disease. On day six post infection, a subset of mice were euthanized
and perfused with PBS for tissue analysis. The remainder of mice were euthanized via isoflur-
ane overdose and cervical dislocation upon losing 20% of their starting body weight or show-
ing signs of severe disease and tissues were collected for titer analysis. No mice died prior
to humane euthanasia. Tissues were homogenized in 1ml PBS, centrifuged to pellet debris,
immediately frozen at -80˚C, then clarified supernatant was used for virus titering as described
above. Survival curves were analyzed by log-rank test. Log-transformed titer data was analyzed
by Mann-Whitney test.
Intracranial infections were performed in 5- to 7-week-old male and female C57BL/6J or
IFNAGR-/- mice with 103 FFU of WT or Δ346 ZIKV in 20ul diluted in PBS into the left cere-
bral hemisphere via insulin syringe while under brief isoflurane anesthesia and monitored as
described above (For IFNAGR-/- mice, n = 11 and 14 respectively. For C57BL/6J mice, n = 15
and 14, respectively). Mice were euthanized on days two, six, or upon losing 20% of their start-
ing weight, and tissue was collected and titered as described above. No mice died prior to
humane euthanasia. Survival curves were analyzed by log-rank test. Log-transformed titer data
was analyzed by two-factor ANOVA followed by Sidak’s multiple comparisons.
Antibody response experiments were performed in five-week-old female C57BL/6J mice,
which were given 1mg of anti-IFNAR1 antibody (MAR1-5A3, Bio X Cell) via intraperitoneal
injection one day prior to footpad infection and monitored as described above (n = 5 mock
infected and n = 8 for each ZIKV infected group). Blood was collected on day three post infec-
tion via submandibular bleed, allowed to clot for at least 10 minutes and clarified by centrifu-
gation prior to storage at -80˚C. Mice were euthanized on day 28 post infection for terminal
blood collection. Log-transformed titer data was analyzed by one-factor ANOVA followed by
Tukey’s multiple comparisons. All mouse experiments were performed once.
Sequencing ZIKV envelope
Virus stock RNA was isolated via Viral RNA Mini Kit (Qiagen). Total brain RNA was isolated
from brain homogenates and TRIzol LS (Invitrogen) and Direct-zol RNA MiniPrep kit (Zymo
Research). cDNA was reverse transcribed using SuperScript III (Invitrogen) using random
primers. The ZIKV envelope sequence was PCR amplified, and PCR amplicon was sequenced
via Sanger sequencing and analyzed in Geneious (Version 11.0.04).
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Enzyme-Linked Immunosorbent Assay (ELISA)
96-well high bind plates were coated with human MAb EDE1 C10, previously shown to bind
WT and Δ346 ZIKV equally [24]. Plates were blocked with 3% non-fat milk, then viral antigen
(WT or Δ346 ZIKV) was captured for one hour at 37˚C. Mouse immune sera was diluted
1:1000 then allowed to bind to captured virus for one hour at 37˚C. Anti-mouse-IgG alkaline
phosphatase labeled secondary antibody was added, plates were developed using p-nitrophenyl
phosphate, and color changes were quantified via spectrophotometry. ELISA data was ana-
lyzed by two-factor ANOVA followed by Tukey’s multiple comparisons.
Focus reduction neutralization test (FRNT)
Plates were seeded with C6/36 cells one day prior to neutralization assay. Mouse immune sera
were serially diluted four-fold beginning at 1:20, then mixed with WT or Δ346 ZIKV viruses
diluted to ~45 FFU/well. Virus:Ab mixture was incubated for one hour at 32˚C, added to C6/
36 cells and incubated for an additional hour at 32˚C. Overlay was added and cells were incu-
bated for 4–6 days, then fixed and immunostained as described above. FRNT data was ana-
lyzed by two-factor ANOVA followed by Tukey’s multiple comparisons.
Supporting information
S1 Data. Raw data of included figures. Microsoft Excel file containing data used to generate
figures in Prism (version 8.0.1). Individual sheets correspond to each figure panel. ZIKV titer
data provided as the log transform of foci forming units per ml or gram of tissue (FFU/ml or
FFU/g). Limits of detection are also provided. Mouse weight data provided in grams and as
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